Update on the pharmacogenomics of proton pump inhibitors

Pharmacogenomics

Volumn 12, Issue 6, 2011, Pages 873-888

  Hagymási, Krisztina ^a   Müllner, Katalin ^a   Herszényi, László ^a   Tulassay, Zsolt ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

gastroesophageal reflux disease; Helicobacter pylori; peptic ulcer; pharmacogenetics; pharmacogenomics; proton pump inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; CARBAMAZEPINE; CLARITHROMYCIN; CLOPIDOGREL; CONTRACEPTIVE AGENT; CYCLOSPORIN; CYTOCHROME P450 2C19; DAPSONE; DIAZEPAM; DIGOXIN; ESOMEPRAZOLE; FLUVOXAMINE; ITRACONAZOLE; KETOCONAZOLE; LANSOPRAZOLE; METHOTREXATE; METRONIDAZOLE; NIFEDIPINE; OMEPRAZOLE; PANTOPRAZOLE; PHENYTOIN; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE; SALICYLIC ACID DERIVATIVE; TACROLIMUS; TICLOPIDINE; WARFARIN;

ACHLORHYDRIA; AREA UNDER THE CURVE; BACTERIAL OVERGROWTH; BARRETT ESOPHAGUS; COST BENEFIT ANALYSIS; DIARRHEA; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; ERADICATION THERAPY; ESOPHAGITIS; FUNDIC GLAND POLYP; GASTRINOMA; GASTRITIS; GASTRODUODENAL ULCER; GASTROESOPHAGEAL REFLUX; GENETIC POLYMORPHISM; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HEPATITIS; HUMAN; HYPERGASTRINEMIA; INTERSTITIAL NEPHRITIS; MALABSORPTION; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PEPTIC ULCER; PHARMACOGENOMICS; POLYP; REFLUX ESOPHAGITIS; REVIEW; SIDE EFFECT; STOMACH ACID SECRETION; STOMACH ULCER; VISUAL DISORDER; ZOLLINGER ELLISON SYNDROME;

ARYL HYDROCARBON HYDROXYLASES; DRUG INTERACTIONS; GASTROESOPHAGEAL REFLUX; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROTON PUMP INHIBITORS;

HELICOBACTER PYLORI;

EID: 79959396924     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.4     Document Type: Review

References (76)

1. Lee K C, Ma JD, Kuo GM: Pharmacogenomics: bridging the gap between science and practice. J. Am. Pharm. Assoc. 50(1), e1-e17 (2010).
2. Mullin JM, Gabello M, Murray LJ et al.: Proton pump inhbitors: actions and reactions. Drug Disc. Today 14(13-14), 647-660 (2009).
3. Yang Y-X, Metz DC: Safety of proton pump inhibitor exposure. Gastroenterology 139(4), 1115-1127 (2010).
4. Shin JM, Sachs G: Pharmacology of proton pump inhibitors. Curr. Gastroenterol. Rep. 10(6), 528-534 (2008).
5. Vanderhoff BT, Tahbouh RM: Proton pump inhibitors: an update. Clin. Pharmacol. 66(2), 273-280 (2002). (Pubitemid 34810080)
6. Robinson M, Horn J: Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs 63(24), 2739-2754 (2003). (Pubitemid 38049991)
7. Ishizaki T, Horai Y: Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment. Pharmacol. Ther. 13(Suppl. 3), 27-36 (1991).
8. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T: Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab. Pharmacokinet. 20(3), 153-167 (2005).
9. Hassan-Alin M, Andersson T, Niazi M, Liljeblad M, Persson BA, Rohss K: Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjects. Int. J. Clin. Pharmacol. Ther. 44(3), 119-127 (2006). (Pubitemid 43338012)
10. Andersson T, Röhss K, Bredberg E, Hassan- Alin M: Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol. Ther. 15(10), 1563-1569 (2001). (Pubitemid 32912398)
11. Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A: Identification of the human P450 enzymes involved in lansoprazole metabolism. J. Pharmacol. Exp. Ther. 277(2), 805-816 (1996). (Pubitemid 27168992)
12. Fitton A, Wiseman L: Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 51(3), 460-482 (1996).
13. Desta ZX, Shin JG, Flockhart DA: Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41(12), 913-958 (2002). (Pubitemid 35168437)
14. Vanden Branden M, Ring BJ, Binkley SN, Wrighton SA: Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. Pharmacogenetics 6(1), 81-91 (1996). (Pubitemid 26097628)
15. Chaudhry AS, Kochhar R, Kohli KK: Genetic polymorphism of CYP2C19 and therapeutic response to proton pump inhibitors. Indian J. Med. Res. 127(6), 521-530 (2008).
16. Zanger UM, Turpeinen M, Klein K, Scwab M: Functional pharmacogenetics/ genomics of human cytochromes P450 involved in drug biotransformation. Anal. Bioanal. Chem. 392(6), 1093-1108 (2008).
17. Bertilsson L: Geographical/interrracial differences in polymorphic drug oxidation. Clin. Pharmacokin. 29(3), 192-209 (1995).
18. Sim SC, Risinger C, Dahl ML et al.: A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther. 79(1), 103-113 (2006). (Pubitemid 43069582)
19. Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J: Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br. J. Clin. Pharmacol. 69(3), 222-230 (2010).
20. Saito YA, Talley NJ: AJG Series: molecular biology for clinicians pharmacogenetics and genomics for clinicians. Am. J. Gastroenterol. 104(10), 2583-2587 (2009).
21. Tanaka M, Ohkubo T, Otani K et al.: Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4́-hydroxylation phenotype and genotype. Clin. Pharmacol. Ther. 62(6), 619-628 (1997). (Pubitemid 28068065)
22. Gardiner SJ, Begg EJ: Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol. Rev. 58(3), 521-590 (2006). (Pubitemid 44403684)
23. Horai Y, Kimura M, Furuie H et al.: Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment Pharmacol. Ther. 15(6), 793-803 (2001). (Pubitemid 32500425)
24. Li X-Q, Andersson TB, Ahlstrom M, Weidolf L: Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab. Dis. 32(8), 821-827 (2004). (Pubitemid 38955611)
25. Miehlke S, Löbe S, Madisch A et al.: Intragastric acidity during administration of generic omeprazole or esomeprazole - a randomised, two-way crossover study including CYP2C19 genotyping. Aliment Pharmacol. Ther. 33(4), 471-476 (2010).
26. Hunfeld NG, Touw DJ, Mathot RA et al.: A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol. Ther. 31(1), 150-159 (2010).
27. Shirai N, Furuta T, Moriyama Y: Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol. Ther. 15(12), 1929-1937 (2001). (Pubitemid 34014349)
28. Sagar M, Tybring G, Dahl M-L, Bertilsson L, Seensalu R: Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism. Gastroenterology 119(3), 670-676 (2000).
29. Furuta T, Shirai N, Takashima M et al.: Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 11(4), 341-348 (2001). (Pubitemid 32537408)
30. Klinkenberg-Knol EC, Festen HP, Jansen JP et al.: Long-term treatment with omeprazol for refractory reflux esophagitis: efficacy and safety. Ann. Intern. Med. 121(3), 161-167 (1994). (Pubitemid 24225631)
31. Shimatani T, Inoue M, Kuroiwa T et al.: Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19. Clin. Pharmacol. Ther. 79(1), 144-152 (2006). (Pubitemid 43069585)
32. Leite LP, Johnston BT, Just RJ, Castell DO: Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am. J. Gastroenterol. 91(8), 1527-1531 (1996). (Pubitemid 26269164)
33. Bertilsson L, Lou YQ, Du YL et al.: Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin. Pharmacol. Ther. 51(4), 388-397 (1992).
34. Ogawa R, Echizen H: Drug-drug interaction profiles of proton pump inhibitors. Clin. Pharmacokinet. 49(8), 509-533 (2010).
35. Trifiro G, Corrao S, Alacqua M et al.: Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources. Br. J. Clin. Pharmacol. 62(5), 582-590 (2006). (Pubitemid 44571580)
36. Humphries TJ, Merritt GJ: Review article: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol. Ther. 13(Suppl. 3), 18-26 (1999). (Pubitemid 29389408)
37. Gerson LB, Triadafilopoulos G: Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur. J. Gastroenterol. Hepatol. 13(5), 611-616 (2001). (Pubitemid 32466269)
38. Ushiama H, Echizen H, Nachi S, Ohnishi A: Dose-dependent inhibition of CYP3A4 activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6b-hydroxycortisol. Clin. Pharmacol. Ther. 72(1), 33-43 (2002). (Pubitemid 34833185)
39. Hassan-Alin M, Andersson T, Niazi M, Liljeblad M, Persson BA, Rohss K. Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjects. Int. J. Clin. Pharmacol. Ther. 44(3), 119-127 (2006). (Pubitemid 43338012)
40. Miura M, Satoh S, Inoue K et al.: Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Ther. Drug Monit. 30(1), 46-51 (2008). (Pubitemid 351161098)
41. Hosohata K, Masuda S, Katsura T et al.: Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but no lansoprazole, in adult living-donor liver transplant patients. Drug Metab. Disp. 37(4), 821-826 (2009).
42. Bhatt DL, Cryer BL, Contant CF et al.: Clopidogrel with or without omeprazole in coronary artery disease. N. Engl. J. Med. 363(20), 1909-1917 (2010).
43. Juhasz M, Herszenyi L, Tulassay ZS: Current standings of the proton pump inhibitor and clopidrogel co-therapy: review on an evolving field with the eyes of the gastroenterologist. Digestion 81(1), 10-15 (2010).
44. Laine L, Hennekens C: Proton pump inhibitor and clopidrogel interaction: fact or fiction? Am. J. Gastroenterol. 105(1), 34-41 (2010).
45. Abraham NS, Hlatky MA, Antman EM et al.: ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A report of the American college of cardiology foundation task force on expert consensus documents. J. Am. Coll. Cardiol. 56(24), 2051- 2066 (2010).
46. Yang YX, Metz DC: Safety of proton pump inhibitor exposure. Gastroenterology 139(4), 111-112 (2010).
47. Southworth MR, Temple R: Interaction of clopidogrel and omeprazole. N. Engl. J. Med. 363(20), 1977 (2010).
48. Thomson ABr Sauve MD, Kasam N, Kamitakahara H: Safety of long-term use of protein pump inhibitors. World J. Gastroenterol 16(19), 2323-2330 (2010).
49. Savarino V, Di Mario F, Scarpignato C: Proton pump inhibitors in GORD. An overview of their pharmacology, efficacy and safety. Pharmacol. Res. 59(3), 135-153 (2009).
50. Moayyedi P: Hip fracture and proton pump inhibitor therapy: position statement. Can. J. Gastroenterol. 22(10), 855-856 (2008).
51. Helsby NA, Lo WY, Simpson IJ et al.: Omeprazole-induced acute interstitial nephritis is not related to CYP2C19 genotype or CYP2C19 phenotype. Br. J. Clin. Pharmacol. 69(5), 516-519 (2010).
52. Peghini PL Katz PO, Castell DO: Ranitidine controls nocturnal acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 115(6), 1335-1339 (1998). (Pubitemid 28545982)
53. Sugimoto M, Furuta T, Shirai N et al.: Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes. Clin. Pharmacol. Ther. 77(4), 302-311 (2005). (Pubitemid 40470386)
54. Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T: Effect of high-dose lansoprazole on intragastric pH in subjects who are homozygous extensive metabolizers of cytochrome P450 2C19. Clin. Pharmacol. Ther. 70(5), 484-492 (2001). (Pubitemid 33135329)
55. Kawamura M, Ohara S, Koike T et al.: The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol. Ther. 17(7), 965-973 (2003). (Pubitemid 36459609)
56. Furuta T, Sugimoto M, Kodaira C et al.: CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole. Eur. J. Clin. Pharmacol. 65(7), 693-698 (2009).
57. Lee YC, Lin JT, Wang HP, Chiu HM, Wu MS: Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease. J. Gastroenterol. Hepatol. 22(8), 1286-1292 (2007).
58. Yamano HO, Matsushita HO, Yanagiwara S: Plasma concentration of rabeprazole after 8-week administration in gastroesophageal reflux disease patients and intragastric pH elevation. J. Gastroenterol. Hepatol. 23(4), 534-540 (2008). (Pubitemid 351501143)
59. Zendehdel N, Biramijamal F, Hossein-Nezhad A et al.: Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis. Arch. Iran. Med. 13(5), 406-412 (2010).
60. Suzuki H, Nishizawa T, Hibi T: Helicobacter pylori eradication therapy. Future Microbiol. 5(4), 639-648 (2010).
61. Miyoshi M, Mizuno M, Ishiki K et al.: A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism. J. Gastroenterol. Hepatol. 16(7), 723-728 (2001). (Pubitemid 34188807)
62. Furuta T, Shirai N, Takashima M et al.: Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin. Pharmacol. Ther. 69(3), 158-168 (2001). (Pubitemid 32225416)
63. Furuta T, Ohashi K, Kamata T et al.: Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann. Intern. Med. 129(12), 1027-1030 (1998). (Pubitemid 29005826)
64. Zhao F, Wang J, Yang Y et al.: Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Helicobacter 13(6), 532-541 (2008).
65. Kang JM, Kim N, Lee DH et al.: Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage. J. Gastroenterol. Hepatol. 23(8 Pt 1), 1287-1291 (2008).
66. Sapone A, Vaira D, Trespidi S et al.: The clinical role of cytochrome P450 genotypes in Helicobacter pylori management. Am. J. Gastroenterol. 98(5), 1010-1015 (2003). (Pubitemid 36733760)
67. Lee JH, Jung HY, Choi KD, Song HJ, Lee GH, Kim JH: The Influence of CYP2C19 polymorphism on eradication of Helicobacter pylori: a prospective randomized study of lansoprazole and rabeprazole. Gut Liver 4(2), 201-206 (2010).
68. Schwab M, Schaeffeler E, Klotz U, Treibe G: CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lanzoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin. Pharmacol. Ther. 76(3), 201-209 (2004). (Pubitemid 39221794)
69. García-Martín E, Martínez C, Pizarro RM et al.: CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin. Pharmacol. Ther. 71(3), 196-204 (2002). (Pubitemid 34271123)
70. Sugimoto M, Furuta T, Yamaoka Y: Influence of inflammatory cytokine polymorphisms on eradication rates of Helicobacter pylori. J. Gastroenterol. Hepatol. 24(11), 1725-1732 (2009).
71. Oh JH, Dong MS, Choi MG et al.: Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin. J. Gastroenterol. Hepatol. 24(2), 294-298 (2009).
72. Furuta T, Sugimoto M, Shirai N et al.: Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori. Aliment Pharmacol. Ther. 26(5), 693-703 (2007). (Pubitemid 47246197)
73. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH: The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am. J. Gastroenterol. 101(7), 1467-1475 (2006). (Pubitemid 43980617)
74. Ando T, Kato H, Sugimoto N et al.: A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences. Dig. Dis. Sci. 50(9), 1625-1631 (2005). (Pubitemid 41203654)
75. Ando T, Ishikawa T, Kokura S, Naito Y, Yoshida N, Yoshikawa T: Endoscopic analysis of gastric ulcer after one week's treatment with omeprazole and rabeprazole in relation to CYP2C19 genotype. Dig. Dis. Sci. 53(4), 933-937 (2008). (Pubitemid 351379828)
76. Furuta T, Shirai N, Kodaira M et al.: Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin. Pharmacol. Ther. 81(4), 521-528 (2007). (Pubitemid 46452299)